Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A new precision medicine model identifies high-benefit patients for SGLT2 inhibitor treatment even when albumin levels appear normal, potentially preventing 10% more kidney failure events than current guidelines that rely solely on albuminu
A 12-week randomized trial demonstrates that dapagliflozin significantly reduces arterial stiffness and modulates fluid dynamics in patients at cardiovascular risk, regardless of diabetes status, providing a mechanistic basis for its broad
A nationwide Danish study suggests SGLT2 inhibitors offer superior protection against chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists in patients with type 2 diabetes, particularly for primary prevention.
The SMARTEST trial investigates whether dapagliflozin should replace metformin as first-line therapy for early type 2 diabetes. Baseline data reveals a surprisingly high microvascular event rate, highlighting the urgent need for early organ
A nationwide target trial emulation study reveals that SGLT2 inhibitors provide cardiovascular benefits across a broader range of patients than previously recognized, with benefit more closely tied to individual metabolic traits than tradit
A nationwide target trial emulation reveals that SGLT2 inhibitors significantly reduce major adverse cardiovascular events and mortality compared to other oral antidiabetics in patients with concurrent T2DM and MASLD, with benefits partiall
A post-hoc analysis of the CANVAS and CREDENCE trials reveals that the kidneyintelX.dkd score significantly improves risk reclassification and monitors the therapeutic impact of canagliflozin in patients with type 2 diabetes and chronic kid
A longitudinal study of 944 heart transplant recipients reveals a staggering incidence of metabolic and renal dysfunction. While diabetes significantly increases mortality risk, the study highlights the potential of SGLT2 inhibitors and GLP
This analysis of the EMPEROR-Reduced trial demonstrates that empagliflozin increases serum magnesium levels and provides a more pronounced reduction in cardiovascular events for patients with low baseline magnesium, revealing a novel electr
A retrospective cohort study validates an algorithm for choosing between SGLT2 and DPP4 inhibitors across diverse UK ethnicity groups, confirming its accuracy for precision medicine while highlighting the necessity of minor recalibration to
A Danish nationwide cohort study found that initiating SGLT2 inhibitors rather than mineralocorticoid receptor antagonists (MRAs) as the third foundational therapy after RASI and beta‑blocker in HFrEF was associated with lower all‑cause and
This review comprehensively summarizes recent studies (2021–2024) from the EMPEROR-Preserved trial, highlighting empagliflozin’s consistent benefits on cardiovascular and renal outcomes, quality of life, and key clinical subgroups in HFpEF
A pooled analysis of five randomized trials (n=26,946) found that severe eGFR deterioration (<25 and <20 ml/min/1.73 m2) increased cardiovascular risk nearly twofold, but SGLT2 inhibitors reduced that risk and retained benefit regardl
An individual participant-level meta-analysis of 23,340 participants shows empagliflozin reduces acute and chronic kidney events, slows eGFR decline, and lowers kidney failure risk regardless of predicted acute eGFR dip, diabetes, heart fai
A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑inter
A pooled analysis of 58,816 participants shows SGLT2 inhibitors lower kidney disease progression, AKI, hospitalizations, and mortality across diabetes status and albuminuria levels, with larger absolute kidney benefits where UACR ≥200 mg/g.
A SMART‑C meta‑analysis of 70,361 participants shows SGLT2 inhibitors reduce CKD progression and kidney failure across eGFR and albuminuria strata, including stage 4 CKD and low albuminuria.
A large propensity-matched cohort study found that baseline SGLT2 inhibitor use versus DPP4 inhibitor therapy in adults with type 2 diabetes and infection was associated with lower 30-day sepsis-induced cardiomyopathy and improved 1-year mo
A 20‑year TriNetX analysis of 913,428 T2DM patients found SGLT2 inhibitor use associated with a 28% lower Parkinson’s disease risk versus metformin (aHR 0.72), suggesting possible superior neuroprotection and prompting need for prospective
A nationwide Taiwanese active-comparator cohort found SGLT2 inhibitor use was associated with a lower incidence of new-onset atopic dermatitis compared with DPP‑4 inhibitors; the effect persisted across sensitivity analyses, showed a dose-r